The expression and functional analysis of the sialyl-T antigen in prostate cancer
- PMID: 32583304
- DOI: 10.1007/s10719-020-09927-x
The expression and functional analysis of the sialyl-T antigen in prostate cancer
Abstract
Aberrant glycosylation is a featured characteristic of cancer and plays a role in cancer pathology; thus an understanding of the compositions and functions of glycans is critical for discovering diagnostic biomarkers and therapeutic targets for cancer. In this study, we used MALDI-TOF-MS analysis to determine the O-glycan profiles of prostate cancer cells metastasized to bone (PC-3), brain (DU145), lymph node (LNCaP), and vertebra (VCaP) in comparison to immortalized RWPE-1 cells derived from normal prostatic tissue. Prostate cancer (CaP) cells exhibited an elevation of simple/short O-glycans, with a reduction of complex O-glycans, increased O-glycan sialylation and decreased fucosylation. Core 1 sialylation was increased dramatically in all CaP cells, and especially in PC-3 cells. The expression of Neu5Acα2-3Galβ1-3GalNAc- (sialyl-3T antigen) which is the product of α2,3-sialyltransferase-I (ST3Gal-I) was substantially increased. We therefore focused on exploring the possible function of ST3Gal-I in PC-3 cells. ST3Gal-I silencing studies showed that ST3Gal-I was associated with PC-3 cell proliferation, migration and apoptosis. Further in vivo studies demonstrated that down regulation of ST3Gal-I reduced the tumor size in xenograft mouse model, indicating that sialyl-3T can serve as a biomarker for metastatic prostate cancer prognosis, and that ST3Gal-I could be a target for therapeutic intervention in cancer treatment.
Keywords: Glycosylation; Mass spectrometry; Prostate cancer; Sialyl-3T antigen; α2,3-sialyltransferase.
Similar articles
-
ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines.BMC Cancer. 2009 Oct 7;9:357. doi: 10.1186/1471-2407-9-357. BMC Cancer. 2009. PMID: 19811634 Free PMC article.
-
Reversible sialylation: synthesis of cytidine 5'-monophospho-N-acetylneuraminic acid from cytidine 5'-monophosphate with alpha2,3-sialyl O-glycan-, glycolipid-, and macromolecule-based donors yields diverse sialylated products.Biochemistry. 2008 Jan 8;47(1):320-30. doi: 10.1021/bi701472g. Epub 2007 Dec 8. Biochemistry. 2008. PMID: 18067323 Free PMC article.
-
Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II.J Proteome Res. 2012 Apr 6;11(4):2609-18. doi: 10.1021/pr201108q. Epub 2012 Feb 29. J Proteome Res. 2012. PMID: 22329400 Free PMC article.
-
The glycosylation landscape of prostate cancer tissues and biofluids.Adv Cancer Res. 2024;161:1-30. doi: 10.1016/bs.acr.2024.04.005. Epub 2024 Apr 25. Adv Cancer Res. 2024. PMID: 39032948 Review.
-
Specific sialylation of N-glycans and its novel regulatory mechanism.Glycoconj J. 2024 Jun;41(3):175-183. doi: 10.1007/s10719-024-10157-8. Epub 2024 Jul 3. Glycoconj J. 2024. PMID: 38958800 Free PMC article. Review.
Cited by
-
Elucidation of the Binding Orientation in α2,3- and α2,6-Linked Neu5Ac-Gal Epitopes toward a Hydrophilic Molecularly Imprinted Monolith.ACS Omega. 2023 Nov 6;8(46):44238-44249. doi: 10.1021/acsomega.3c06836. eCollection 2023 Nov 21. ACS Omega. 2023. PMID: 38027366 Free PMC article.
-
In-Depth Glycoproteomic Assay of Urinary Prostatic Acid Phosphatase.ACS Meas Sci Au. 2023 Dec 8;4(1):117-126. doi: 10.1021/acsmeasuresciau.3c00055. eCollection 2024 Feb 21. ACS Meas Sci Au. 2023. PMID: 38404489 Free PMC article.
-
Electrochemical Evaluation of Tumor Development via Cellular Interface Supported CRISPR/Cas Trans-Cleavage.Research (Wash D C). 2022 Apr 6;2022:9826484. doi: 10.34133/2022/9826484. eCollection 2022. Research (Wash D C). 2022. PMID: 35474904 Free PMC article.
-
Sialylation: A Cloak for Tumors to Trick the Immune System in the Microenvironment.Biology (Basel). 2023 Jun 8;12(6):832. doi: 10.3390/biology12060832. Biology (Basel). 2023. PMID: 37372117 Free PMC article. Review.
-
Galectin-3 and Epithelial MUC1 Mucin-Interactions Supporting Cancer Development.Cancers (Basel). 2023 May 9;15(10):2680. doi: 10.3390/cancers15102680. Cancers (Basel). 2023. PMID: 37345016 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous